Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-05-21 Management Reports
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Management Reports 2019
Management Reports Classification · 1% confidence The document provides a detailed financial update covering the 'First quarter' results (Q1 2019), significant events during that quarter, post-period events up to May 2019, and a CEO commentary. It includes specific financial metrics (net profit/loss, fair value, cash), operational updates on portfolio companies' clinical trials, and management's discussion of financial strategy (convertible loan). This structure, focusing on quarterly performance and management discussion, strongly indicates an Interim/Quarterly Report. The mention of the 'Annual Report' in the post-period events section confirms that this document is distinct from the full annual filing (10-K) and serves as the comprehensive report for a shorter period. Therefore, the classification is Interim / Quarterly Report (IR).
2019-05-21 English
Karolinska Developments portföljbolag OssDsigns nyemission inför notering på Nasdaq First North är övertecknad
Share Issue/Capital Change Classification · 1% confidence The document announces that a portfolio company, OssDsign, has oversubscribed its rights issue ('nyemission') ahead of its listing on Nasdaq First North, raising approximately 151.3 MSEK. This involves the issuance of new shares and changes in ownership percentages for the parent company, Karolinska Development. This activity directly relates to fundraising, financing activities, and capital structure changes for the portfolio company, which is reported by the investment company (Karolinska Development). This fits the definition of 'Capital/Financing Update' (CAP). It is not a formal regulatory report like a 10-K or IR, nor is it a general earnings release or dividend notice. It is a specific announcement about a capital event.
2019-05-20 Swedish
Karolinska Development’s portfolio company OssDsign’s share issue prior to listing on Nasdaq First North is oversubscribed
Share Issue/Capital Change Classification · 1% confidence The document is an announcement from Karolinska Development regarding its portfolio company, OssDsign, completing an oversubscribed share issue prior to its listing on Nasdaq First North. The core subject is the successful fundraising and capital structure change (share issue) of an associated entity, which directly relates to capital/financing activities. This aligns best with the 'Capital/Financing Update' category (CAP). Although it involves shares, it is a report on the *completion* of a financing round, not a general announcement of a share repurchase (POS) or a general share issue announcement (SHA) by the reporting entity itself, but rather a specific financing event for a portfolio company.
2019-05-20 English
Karolinska Development's portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell disease
Legal Proceedings Report Classification · 1% confidence The document is a press release from Karolinska Development AB announcing clinical trial results for a portfolio company's drug (sevuparin). It details the outcome of a Phase 2 study regarding acute vaso-occlusive crisis in sickle cell disease patients. This type of announcement, focusing on operational or clinical milestones rather than comprehensive financial results (like a 10-K or IR), is typically classified as a general regulatory announcement or news release. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific legal/governance filing, and it serves as a material update to the market, it fits best under the general 'Regulatory Filings' (RNS) category, which acts as a catch-all for significant, non-standard announcements. The document length (3929 chars) is short enough that it is not a full report, but a direct announcement.
2019-05-13 English
Karolinska Developments portföljbolag Modus Therapeutics tillkännager resultat från en fas 2-studie av sevuparin i patienter med sicklecellsjukdom
Regulatory Filings Classification · 1% confidence The document is a press release from Karolinska Development AB announcing the results of a Phase 2 clinical trial for its portfolio company, Modus Therapeutics. The content focuses on the outcome of a specific medical study (failure to show meaningful clinical effect) and the subsequent strategic review. This type of announcement, detailing clinical trial progress or setbacks, is typically classified as an Earnings Release (ER) if it contains key financial/operational highlights, or sometimes as Regulatory Filings (RNS) if it's a mandatory disclosure. Given that it is a specific operational update announcing key results (even negative ones) and strategic implications, it aligns best with the 'Earnings Release' (ER) category, which often encompasses significant operational milestones that impact valuation, even if it's not a standard quarterly earnings report. The final sentence confirms it is information the company is obligated to disclose under EU market abuse regulation, suggesting a mandatory public disclosure, which often falls under ER or RNS. Since it details a major operational event (trial results), ER is a strong fit, though RNS is a possible fallback. I will classify it as ER as it functions as a major operational update.
2019-05-13 Swedish
Karolinska Development’s portfolio company OssDsign applies for listing on Nasdaq First North
Report Publication Announcement Classification · 1% confidence The document announces that a portfolio company, OssDsign, is applying for listing on Nasdaq First North and is conducting a share issue of SEK 151.3 million. This involves the creation of new shares and capital raising activities. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising, financing activities, or capital structure changes. Although it mentions a prospectus being published, the core subject is the capital raise and listing application, making CAP more specific than RPA or RNS.
2019-05-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.